AAV-Binding Nanobody Sequences for Scalable Affinity Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant adeno-associated virus (rAAV) are cumbersome, costly, and inefficient, particularly due to the challenges of removing host cell proteins (HCPs) and the variability in affinity, stability, and binding spectrum of traditional antibody-based methods, which hinder scalable and cost-effective industrial applications.
Innovation Solution
Development of specific amino acid sequences for nanobodies with defined complementarity-determining regions (CDRs) and framework regions (FRs) that enable high-affinity binding to AAV, allowing for efficient purification and detection through affinity chromatography, including multivalent synthesis and humanized nanobodies for enhanced performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibody-based methods are used for AAV purification, then AAV binding is achieved, but the process becomes costly and complex with variable affinity and stability
Solution Approach 1:
The invention extracts only the essential binding domain (VHH/nanobody) from the complete antibody structure. This nanobody comprises specifically defined CDR1, CDR2, and CDR3 regions with precise amino acid sequences that maintain AAV binding capability while eliminating the complex constant regions and other antibody components, thereby simplifying the purification process while preserving binding reliability
Solution Approach 2:
The invention creates simplified copies of the antibody's binding function using nanobodies that replicate the antigen-binding capability through precisely engineered CDR regions. These nanobody copies provide consistent and reliable AAV binding without requiring the full antibody structure, reducing process complexity while maintaining binding affinity
2Reliability
If multiple purification steps are used to remove HCPs, then purification effectiveness is improved, but overall yield decreases and process becomes less scalable
Solution Approach 1:
The nanobody-based affinity chromatography medium performs multiple purification functions simultaneously. It captures AAV particles while allowing HCPs to pass through, achieving both virus concentration and contaminant removal in a single step. This multi-functional approach eliminates the need for separate purification steps, maintaining high purification effectiveness while preserving overall yield and enabling scalability
3Reliability
If conventional chromatography methods are used, then AAV purification is achieved, but the process is not suitable for large-volume lysates and lacks scalability
Solution Approach 1:
The invention changes the key parameter of the binding agent from traditional antibodies to nanobodies with specifically defined CDR sequences. This parameter change enables the development of affinity chromatography media that can handle large volumes while maintaining purification effectiveness. The nanobody's smaller size and engineered properties allow for optimized flow rates and binding capacities suitable for industrial-scale applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanobody-based approach provides a scalable and cost-effective solution for rAAV purification with high specificity and yield, suitable for industrial applications, and supports both purification and detection of AAV.
Implementation Method 1
nanobodies with defined complementarity-determining regions (CDRs) and framework regions (FRs) that enable high-affinity binding to AAV, allowing for efficient purification and detection through affinity chromatography
Data Source
AI summary
Provided herein are nanobodies, polypeptides comprising the same, and uses thereof. The nanobody's variable region includes 3 complementarity determining regions (CDRs) and framework regions (FRs), wherein the CDRs are as follows: CDR1: Ser-Gly-Xaa11-Xaa12-Phe-Xaa13-Xaa14-Asn-Xaa15 (Formula I); CDR2: Xaa21-Thr-Xaa22-Xaa23-Gly-Xaa24-Thr (Formula II); CDR3: His-Xaa31-Asp-Glu-Xaa32-Arg-Xaa33-Ser-Xaa34-Trp-Thr-Thr-Ser-Asn-Xaa35 (Formula III). The nanobodies and their polypeptides exhibit high affinity and activity, specifically recognizing and binding AAV. Affinity agents prepared therefrom have strong AAV adsorption capacity, suitable for AAV affinity chromatography to facilitate its industrial application. They are also applicable to AAV detection, enabling simultaneous detection of empty capsids and viral particles.